Compare Amgen, Inc. (AMGN) vs Workday Inc (WDAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Workday Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Workday Inc trades at $141 (market cap $34.32B). The key difference: Amgen, Inc. is far larger — about 5.7× Workday Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Workday Inc pays none. Which is the better fit depends on your goals.
| AMGN | WDAY | |
|---|---|---|
Market Cap | $196.12B | $34.32B |
Sector | Health | Technology |
52-Week High | $388.16 | $247.69 |
52-Week Low | $271.18 | $112.55 |
Enterprise Value | $241.41B | $33.77B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Workday (WDAY) trades at $138.95, up 0.44% with a bullish technical signal. The stock shows strong fundamental momentum with Q1 2026 EPS beating expectations at $2.66 versus $2.51, continuing a trend of earnings outperformance. Revenue growth remains robust, projected to reach $9.9B in 2026, while the company maintains high gross margins of 75.77%. Recent news highlights AI-driven product growth with agentic AI ACV tripling year-over-year.
The outlook remains positive with a $157.30 analyst consensus price target representing 13% upside. Key opportunities include AI adoption driving larger expansion deals, while risks involve a pending California lawsuit over AI bias allegations and elevated valuation multiples. Operating cash flow strength at $2.46B supports continued investment in growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
